Coherus BioSciences
NasdaqGM:CHRS Community- 1 Narratives written by author
- 1 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
AL
AlexanderD
Community Contributor
Coherus BioSciences will see 16% revenue growth driving future value
Coherus is a promising company that did a bad borrowing and has more than paid the price. Its convertible bondholders created a short hedge and have inflicted massive damage on the company's SP.
View narrativeUS$15.42
FV
93.2% undervalued intrinsic discount16.00%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Updated narrative